Suppr超能文献

基于氟达拉滨的预处理方案后,对1H型黏多糖贮积症(胡勒氏病)患儿进行异基因CD34选择干细胞移植。

Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).

作者信息

Grigull L, Beilken A, Schrappe M, Das A, Luecke T, Sander A, Stanulla M, Rehe K, Sauer M, Schmid H, Welte K, Lukacs Z, Gal A, Sykora K W

机构信息

Pediatric Hematology and Oncology, Children's Hospital, Hannover Medical University, Hannover, Germany.

出版信息

Bone Marrow Transplant. 2005 Feb;35(3):265-9. doi: 10.1038/sj.bmt.1704786.

Abstract

Hurler syndrome (MPS1H) is a progressive inborn error of mucopolysaccharide metabolism leading to premature death. Allogeneic hematopoietic cell transplantation (HCT) can achieve stabilization and improve long-term survival. However, large studies have shown that preparative regimen-related toxicity (RRT) and graft failure rates have been relatively high. We transplanted five Hurler children with a fludarabine-based conditioning regimen, consisting of fludarabine/busulphan/ATG for matched family donor (MFD), with the addition of melphalan for mismatched family donor and matched unrelated donor (MUD) transplantations. Median age at HCT was 27 months (range 10-36). The source of stem cells was bone marrow in one MFD and CD34-selected PBSC in four patients. Median CD34+ cell dose was 25 x 10(6)/kg (range 11.5-54). No RRT > grade II was observed. All patients are surviving at a median of 32 months (range 14-41) and show sustained donor engraftment with 3/5 having full donor chimerism, and 2/5 mixed chimerism (> 85%). We conclude that this regimen is feasible and has low toxicity in Hurler children. In combination with high doses of CD34+ selected cells (> 10 x 10(6)/kg) and donor lymphocyte infusions, stable engraftment could be achieved in unrelated and mismatched related transplantations.

摘要

黏多糖贮积症Ⅰ型(胡尔勒综合征,MPS1H)是一种进行性先天性黏多糖代谢障碍疾病,可导致过早死亡。异基因造血细胞移植(HCT)可实现病情稳定并提高长期生存率。然而,大型研究表明,预处理方案相关毒性(RRT)和移植失败率一直相对较高。我们采用了一种以氟达拉滨为基础的预处理方案对5名患有胡尔勒综合征的儿童进行移植,对于匹配的家族供体(MFD),该方案由氟达拉滨/白消安/抗胸腺细胞球蛋白组成,对于不匹配的家族供体和匹配的无关供体(MUD)移植,则添加美法仑。HCT时的中位年龄为27个月(范围10 - 36个月)。1例MFD患者的干细胞来源为骨髓,4例患者为CD34选择的外周血干细胞。CD34 +细胞中位剂量为25×10⁶/kg(范围11.5 - 54)。未观察到RRT > Ⅱ级的情况。所有患者均存活,中位生存期为32个月(范围14 - 41个月),均显示供体持续植入,5例中有3例为完全供体嵌合,2例为混合嵌合(> 85%)。我们得出结论,该方案对患有胡尔勒综合征的儿童是可行的且毒性较低。结合高剂量的CD34 +选择细胞(> 10×10⁶/kg)和供体淋巴细胞输注,在无关和不匹配相关移植中可实现稳定植入。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验